• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

识别继发性免疫缺陷患者中新兴的严重急性呼吸综合征冠状病毒2(SARS-CoV-2)变体的标志物。

Identifying Markers of Emerging SARS-CoV-2 Variants in Patients With Secondary Immunodeficiency.

作者信息

Markarian Nathan M, Galli Gaël, Patel Dhanesh, Hemmings Mark, Nagpal Priya, Berghuis Albert M, Abrahamyan Levon, Vidal Silvia M

机构信息

Department of Human Genetics, McGill University, Montréal, QC, Canada.

McGill University Research Centre on Complex Traits, Montréal, QC, Canada.

出版信息

Front Microbiol. 2022 Jul 1;13:933983. doi: 10.3389/fmicb.2022.933983. eCollection 2022.

DOI:10.3389/fmicb.2022.933983
PMID:35847101
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9283111/
Abstract

Since the end of 2019, the world has been challenged by the coronavirus disease 2019 (COVID-19) pandemic. With COVID-19 cases rising globally, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to evolve, resulting in the emergence of variants of interest (VOI) and of concern (VOC). Of the hundreds of millions infected, immunodeficient patients are one of the vulnerable cohorts that are most susceptible to this virus. These individuals include those with preexisting health conditions and/or those undergoing immunosuppressive treatment (secondary immunodeficiency). In these cases, several researchers have reported chronic infections in the presence of anti-COVID-19 treatments that may potentially lead to the evolution of the virus within the host. Such variations occurred in a variety of viral proteins, including key structural ones involved in pathogenesis such as spike proteins. Tracking and comparing such mutations with those arisen in the general population may provide information about functional sites within the SARS-CoV-2 genome. In this study, we reviewed the current literature regarding the specific features of SARS-CoV-2 evolution in immunocompromised patients and identified recurrent amino acid changes in virus isolates of these patients that can potentially play an important role in SARS-CoV-2 pathogenesis and evolution.

摘要

自2019年底以来,世界一直受到2019冠状病毒病(COVID-19)大流行的挑战。随着全球COVID-19病例的增加,严重急性呼吸综合征冠状病毒2(SARS-CoV-2)持续演变,导致出现了感兴趣的变异株(VOI)和值得关注的变异株(VOC)。在数亿感染者中,免疫缺陷患者是最易感染这种病毒的脆弱群体之一。这些个体包括那些有基础健康状况的人和/或正在接受免疫抑制治疗的人(继发性免疫缺陷)。在这些情况下,一些研究人员报告称,在接受抗COVID-19治疗的情况下出现了慢性感染,这可能会导致病毒在宿主体内进化。这种变异发生在多种病毒蛋白中,包括参与发病机制的关键结构蛋白,如刺突蛋白。追踪并比较这些突变与普通人群中出现的突变,可能会提供有关SARS-CoV-2基因组内功能位点的信息。在本研究中,我们回顾了当前关于免疫受损患者中SARS-CoV-2进化的特定特征的文献,并确定了这些患者病毒分离株中反复出现的氨基酸变化,这些变化可能在SARS-CoV-2发病机制和进化中发挥重要作用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e78a/9283111/d5724a86ff9e/fmicb-13-933983-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e78a/9283111/50bc857d49d2/fmicb-13-933983-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e78a/9283111/3bf049d3ceef/fmicb-13-933983-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e78a/9283111/7b76e96fe440/fmicb-13-933983-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e78a/9283111/5f1711213c6f/fmicb-13-933983-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e78a/9283111/a41c65afd1f9/fmicb-13-933983-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e78a/9283111/d5724a86ff9e/fmicb-13-933983-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e78a/9283111/50bc857d49d2/fmicb-13-933983-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e78a/9283111/3bf049d3ceef/fmicb-13-933983-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e78a/9283111/7b76e96fe440/fmicb-13-933983-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e78a/9283111/5f1711213c6f/fmicb-13-933983-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e78a/9283111/a41c65afd1f9/fmicb-13-933983-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e78a/9283111/d5724a86ff9e/fmicb-13-933983-g006.jpg

相似文献

1
Identifying Markers of Emerging SARS-CoV-2 Variants in Patients With Secondary Immunodeficiency.识别继发性免疫缺陷患者中新兴的严重急性呼吸综合征冠状病毒2(SARS-CoV-2)变体的标志物。
Front Microbiol. 2022 Jul 1;13:933983. doi: 10.3389/fmicb.2022.933983. eCollection 2022.
2
Genetic Surveillance of SARS-CoV-2 M Reveals High Sequence and Structural Conservation Prior to the Introduction of Protease Inhibitor Paxlovid.SARS-CoV-2 M 基因监测显示,在引入蛋白酶抑制剂帕克洛维德之前,其序列和结构高度保守。
mBio. 2022 Aug 30;13(4):e0086922. doi: 10.1128/mbio.00869-22. Epub 2022 Jul 13.
3
The British variant of the new coronavirus-19 (Sars-Cov-2) should not create a vaccine problem.新冠病毒-19(Sars-Cov-2)的英国变体不应造成疫苗问题。
J Biol Regul Homeost Agents. 2021 Jan-Feb;35(1):1-4. doi: 10.23812/21-3-E.
4
Emergence of Multiple SARS-CoV-2 Antibody Escape Variants in an Immunocompromised Host Undergoing Convalescent Plasma Treatment.免疫功能低下宿主接受恢复期血浆治疗后出现多种 SARS-CoV-2 抗体逃逸变异体。
mSphere. 2021 Aug 25;6(4):e0048021. doi: 10.1128/mSphere.00480-21.
5
Emergence, evolution, and vaccine production approaches of SARS-CoV-2 virus: Benefits of getting vaccinated and common questions.严重急性呼吸综合征冠状病毒2(SARS-CoV-2)病毒的出现、演变及疫苗生产方法:接种疫苗的益处及常见问题
Saudi J Biol Sci. 2022 Apr;29(4):1981-1997. doi: 10.1016/j.sjbs.2021.12.020. Epub 2021 Dec 13.
6
Host Response to SARS-CoV2 and Emerging Variants in Pre-Existing Liver and Gastrointestinal Diseases.宿主对 SARS-CoV2 及现有肝脏和胃肠道疾病中新兴变异株的反应。
Front Cell Infect Microbiol. 2021 Oct 25;11:753249. doi: 10.3389/fcimb.2021.753249. eCollection 2021.
7
Emergency SARS-CoV-2 Variants of Concern: Novel Multiplex Real-Time RT-PCR Assay for Rapid Detection and Surveillance.关注的紧急 SARS-CoV-2 变异株:用于快速检测和监测的新型多重实时 RT-PCR 检测方法。
Microbiol Spectr. 2022 Feb 23;10(1):e0251321. doi: 10.1128/spectrum.02513-21.
8
Identification of SARS-CoV-2 Variants of Concern Using Amplicon Next-Generation Sequencing.使用扩增子下一代测序鉴定 SARS-CoV-2 关注变体。
Microbiol Spectr. 2022 Aug 31;10(4):e0073622. doi: 10.1128/spectrum.00736-22. Epub 2022 Jun 27.
9
Current Strategies of Antiviral Drug Discovery for COVID-19.新型冠状病毒肺炎抗病毒药物研发的当前策略
Front Mol Biosci. 2021 May 13;8:671263. doi: 10.3389/fmolb.2021.671263. eCollection 2021.
10
Identification of a High-Frequency Intrahost SARS-CoV-2 Spike Variant with Enhanced Cytopathic and Fusogenic Effects.鉴定具有增强致细胞病变和融合作用的 SARS-CoV-2 高频宿主内刺突变异株。
mBio. 2021 Jun 29;12(3):e0078821. doi: 10.1128/mBio.00788-21.

引用本文的文献

1
Efficient assay for evaluating drug efficacy and synergy against emerging SARS-CoV-2 strains.用于评估针对新出现的严重急性呼吸综合征冠状病毒2(SARS-CoV-2)毒株的药物疗效和协同作用的高效检测方法。
Antimicrob Agents Chemother. 2025 Feb 13;69(2):e0123324. doi: 10.1128/aac.01233-24. Epub 2024 Dec 17.
2
Integration of individualized and population-level molecular epidemiology data to model COVID-19 outcomes.整合个体化和人群水平的分子流行病学数据来建立 COVID-19 结局模型。
Cell Rep Med. 2024 Jan 16;5(1):101361. doi: 10.1016/j.xcrm.2023.101361.
3
Editorial: Immune determinants of COVID-19 protection and disease: A focus on asymptomatic COVID and long COVID.

本文引用的文献

1
The SARS-CoV-2 spike L452R-E484Q variant in the Indian B.1.617 strain showed significant reduction in the neutralization activity of immune sera.印度B.1.617毒株中的新冠病毒刺突蛋白L452R-E484Q变体在免疫血清的中和活性方面表现出显著降低。
Precis Clin Med. 2021 Jul 30;4(3):149-154. doi: 10.1093/pcmedi/pbab016. eCollection 2021 Sep.
2
De novo emergence of a remdesivir resistance mutation during treatment of persistent SARS-CoV-2 infection in an immunocompromised patient: a case report.免疫功能低下患者持续性 SARS-CoV-2 感染治疗过程中雷米昔韦耐药突变的从头出现:一例病例报告。
Nat Commun. 2022 Mar 17;13(1):1547. doi: 10.1038/s41467-022-29104-y.
3
社论:COVID-19 保护和疾病的免疫决定因素:聚焦无症状 COVID 和长期 COVID。
Front Immunol. 2023 Mar 28;14:1185693. doi: 10.3389/fimmu.2023.1185693. eCollection 2023.
4
Identification of natural compounds as SARS-CoV-2 inhibitors molecular docking and molecular dynamic simulation.鉴定天然化合物作为新型冠状病毒 2 抑制剂:分子对接和分子动力学模拟
Front Microbiol. 2023 Feb 1;13:1095068. doi: 10.3389/fmicb.2022.1095068. eCollection 2022.
5
Autoimmunity and Immunodeficiency in Severe SARS-CoV-2 Infection and Prolonged COVID-19.重症新型冠状病毒肺炎感染及新冠后综合征中的自身免疫与免疫缺陷
Curr Issues Mol Biol. 2022 Dec 21;45(1):33-50. doi: 10.3390/cimb45010003.
Viro-immunological evaluation in an immunocompromised patient with long-lasting SARS-CoV-2 infection.
对一名患有长期新冠病毒2型(SARS-CoV-2)感染的免疫功能低下患者的病毒免疫学评估。
Emerg Microbes Infect. 2022 Dec;11(1):786-789. doi: 10.1080/22221751.2022.2045877.
4
SARS-CoV-2 prolonged infection during advanced HIV disease evolves extensive immune escape.在晚期 HIV 疾病中,SARS-CoV-2 持续感染会导致广泛的免疫逃逸。
Cell Host Microbe. 2022 Feb 9;30(2):154-162.e5. doi: 10.1016/j.chom.2022.01.005. Epub 2022 Jan 14.
5
SARS-CoV-2 Evolution and Spike-Specific CD4+ T-Cell Response in Persistent COVID-19 with Severe HIV Immune Suppression.严重HIV免疫抑制的持续性新冠肺炎患者中SARS-CoV-2的进化及刺突特异性CD4+ T细胞反应
Microorganisms. 2022 Jan 11;10(1):143. doi: 10.3390/microorganisms10010143.
6
Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift.广谱中和抗体可克服 SARS-CoV-2 奥密克戎抗原漂移。
Nature. 2022 Feb;602(7898):664-670. doi: 10.1038/s41586-021-04386-2. Epub 2021 Dec 23.
7
Analysis of Immune Escape Variants from Antibody-Based Therapeutics against COVID-19: A Systematic Review.基于抗体的 COVID-19 治疗药物的免疫逃逸变异体分析:系统评价。
Int J Mol Sci. 2021 Dec 21;23(1):29. doi: 10.3390/ijms23010029.
8
SARS-CoV-2 non-structural protein 6 triggers NLRP3-dependent pyroptosis by targeting ATP6AP1.SARS-CoV-2 非结构蛋白 6 通过靶向 ATP6AP1 触发 NLRP3 依赖性细胞焦亡。
Cell Death Differ. 2022 Jun;29(6):1240-1254. doi: 10.1038/s41418-021-00916-7. Epub 2022 Jan 8.
9
The SARS-CoV-2 Lambda variant exhibits enhanced infectivity and immune resistance.SARS-CoV-2 Lambda 变体表现出增强的感染力和免疫抗性。
Cell Rep. 2022 Jan 11;38(2):110218. doi: 10.1016/j.celrep.2021.110218. Epub 2021 Dec 18.
10
A Conservative Replacement in the Transmembrane Domain of SARS-CoV-2 ORF7a as a Putative Risk Factor in COVID-19.严重急性呼吸综合征冠状病毒2(SARS-CoV-2)开放阅读框7a(ORF7a)跨膜结构域中的保守替换作为冠状病毒病(COVID-19)的一个潜在危险因素
Biology (Basel). 2021 Dec 5;10(12):1276. doi: 10.3390/biology10121276.